Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) has shown a year-to-date increase of approximately 9%, with a notable rise of 14% prior to the announcement of its collaboration with AstraZeneca on January 30. The valuation remains attractive, with expectations for more licensing opportunities in the EGFR ADC and R&D platforms [1] Group 1: Stock Performance and Valuation - CSPC's stock price increased by over 3%, currently trading at HKD 9.92, with a trading volume of HKD 378 million [1] - HSBC Research has raised revenue forecasts for CSPC for 2025 to 2027 by 3% to 11%, considering prepayments and slight improvements in last quarter sales [1] - The net profit forecast for 2025 to 2027 has been increased by 7% to 18%, indicating that growth in licensing revenue can offset negative impacts from centralized procurement policies [1] Group 2: Business Development and Future Earnings - Citi expects that completed business development (BD) transactions will start generating recurring revenue from this year [1] - CSPC has secured four significant BD transactions with AstraZeneca and Madrigal Pharmaceuticals, projected to yield approximately USD 10.2 billion in upfront and milestone payments, significantly boosting profits to RMB 6.3 billion, 10.2 billion, and 10.9 billion for 2025 to 2027 [1]
石药集团涨超3% 机构看好公司未来在EGFR ADC及研发平台将有更多对外授权合作机会